The core of the CMO CDMO Market segment is defined by its service offerings, broadly divided into development (CDMO) and manufacturing (CMO). Within manufacturing, Active Pharmaceutical Ingredient (API) production currently holds the largest share, reflecting the foundational need for raw drug substance supply for all pharmaceutical products. This segment is characterized by high-volume, long-term contracts for both small molecule APIs and increasingly, complex biologic APIs, which require large bioreactors and specialized purification techniques.

However, the fastest expansion within the CMO CDMO Market segment is projected in the Finished Dosage Formulation (FDF) sector, particularly for sterile injectables and specialized forms like oral solids. Pharmaceutical companies are consolidating their supply chain under single CDMO partners, requiring seamless technological transfer from API production right through to fill-finish and sterile packaging. The growing prevalence of chronic diseases and the resulting demand for complex injectable therapies, coupled with the rising global consumption of generic medicines, is rapidly boosting the FDF manufacturing segment's value.